WHI Trust’s Cyclerion Therapeutics CYCN Stock Holding History

WHI Trust’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$244	Hold	72	–	–	﹤0.01%	59
2026 Q1	$112	Hold	72	–	–	﹤0.01%	87
2025 Q4	$91	Buy	+72	New	+$129	﹤0.01%	94

Other funds holding CYCN

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

WHI Trust's CYCN Position: Q2 2026 in Review

WHI Trust held its Cyclerion Therapeutics (CYCN) position steady in Q2 2026 at 72 shares worth $244. The position accounts for ﹤0.01% of the portfolio, ranked #59.

WHI Trust first reported a position in CYCN in Q4 2025 and has held it in 3 quarters since. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

WHI Trust held 72 shares of Cyclerion Therapeutics worth $244 as of Q2 2026.
WHI Trust left its Cyclerion Therapeutics share count unchanged in Q2 2026.
Cyclerion Therapeutics made up ﹤0.01% of WHI Trust's portfolio in Q2 2026, its #59 holding.
WHI Trust first reported a position in Cyclerion Therapeutics in Q4 2025 and has held it in 3 quarters since.
21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on WHI Trust's 13F filing for Q2 2026, filed 11 Aug 2026.